Pinter A - Search Results

1

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, Honnen WJ, Kayman SC, Krachmarov C, Pinter A, Zolla-Pazner S. Gorny MK, et al. Among authors: pinter a. J Virol. 2002 Sep;76(18):9035-45. doi: 10.1128/jvi.76.18.9035-9045.2002. J Virol. 2002. PMID: 12186887 Free PMC article.

2

Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU.

Burkhart MD, Kayman SC, He Y, Pinter A. Burkhart MD, et al. Among authors: pinter a. J Virol. 2003 Apr;77(7):3993-4003. doi: 10.1128/jvi.77.7.3993-4003.2003. J Virol. 2003. PMID: 12634359 Free PMC article.

3

The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S. Gorny MK, et al. Among authors: pinter a. J Virol. 2004 Mar;78(5):2394-404. doi: 10.1128/jvi.78.5.2394-2404.2004. J Virol. 2004. PMID: 14963135 Free PMC article.

4

The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.

Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. Pinter A, et al. J Virol. 2004 May;78(10):5205-15. doi: 10.1128/jvi.78.10.5205-5215.2004. J Virol. 2004. PMID: 15113902 Free PMC article.

5

Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN, Zolla-Pazner S, Kayman SC. Krachmarov C, et al. Among authors: pinter a. J Virol. 2005 Jan;79(2):780-90. doi: 10.1128/JVI.79.2.780-790.2005. J Virol. 2005. PMID: 15613306 Free PMC article.

6

The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.

Pinter A, Honnen WJ, D'Agostino P, Gorny MK, Zolla-Pazner S, Kayman SC. Pinter A, et al. J Virol. 2005 Jun;79(11):6909-17. doi: 10.1128/JVI.79.11.6909-6917.2005. J Virol. 2005. PMID: 15890930 Free PMC article.

7

Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, Burda S, Kimura T, Konings FA, Nádas A, Anyangwe CA, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S. Gorny MK, et al. Among authors: pinter a. J Virol. 2006 Jul;80(14):6865-72. doi: 10.1128/JVI.02202-05. J Virol. 2006. PMID: 16809292 Free PMC article.

8

Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.

Krachmarov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A. Krachmarov CP, et al. Among authors: pinter a. J Virol. 2006 Jul;80(14):7127-35. doi: 10.1128/JVI.02619-05. J Virol. 2006. PMID: 16809318 Free PMC article.

9

Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.

Zolla-Pazner S, Cohen SS, Krachmarov C, Wang S, Pinter A, Lu S. Zolla-Pazner S, et al. Among authors: pinter a. Virology. 2008 Mar 15;372(2):233-46. doi: 10.1016/j.virol.2007.09.024. Epub 2007 Dec 3. Virology. 2008. PMID: 18061228 Free article.

10

Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Gorny MK, Wang XH, Williams C, Volsky B, Revesz K, Witover B, Burda S, Urbanski M, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S, Nadas A. Gorny MK, et al. Among authors: pinter a. Mol Immunol. 2009 Feb;46(5):917-26. doi: 10.1016/j.molimm.2008.09.005. Epub 2008 Oct 25. Mol Immunol. 2009. PMID: 18952295 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

688 results

Search Page

Filters